Search results for EASD2026
EASD2026 community
One keyword maps to one global community path.
People
Not Found
Tweets including EASD2026
Presented at #EASD2026#, our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results in adults with obesity and type 2 diabetes: substantial weight loss and A1C reduction. Read more:
Show more
New information for HCPs: A new indirect treatment comparison presented at the #EASD2026# annual meeting compared the highest dose of our dual GIP/GLP-1 obesity medicine with the highest dose of another obesity medicine. Read more:
Show more
NOVO’S WEGOVY® (SEMAGLUTIDE) REDUCED LIVER FAT TO NORMAL LEVELS IN 9 OUT OF 10 ADULTS WITH OBESITY AND EXCESS LIVER FAT – EASD2026
Treating obesity & type 2 diabetes together can be challenging, but new research presented at #EASD2026# showed our investigational treatment, when taken at the highest dose, helped more than half of participants no longer have obesity, and nearly 40% reach a normal A1C.
Show more
New evidence for HCPs: A new indirect treatment comparison, shared today at #EASD2026#, evaluated the highest dose of our oral GLP-1 alongside a higher dose of another oral medicine for type 2 diabetes:
Show more
The heart deserves as much attention as blood sugar in type 2 diabetes. In our largest, longest study of an oral GLP-1, presented at #EASD2026#, the trial met its cardiovascular safety endpoint vs. insulin glargine. Read more:
Show more
What do people living with obesity need for their long-term care? We’re at @EASDNews talking about patient-centered care and research.
See what we’re discussing. ➡️ #EASD2026#
Show more
In Milan, Italy, we're opening House of Lilly during #EASD2026#. It brings art and science together to share our history, the inspiration behind our innovation and the science behind what comes next as we work to change the course of cardiometabolic health.
#WeAreLilly#
Show more
Obesity and type 2 diabetes rarely occur alone. That's why it's important to have treatment options that address different patient's needs. This is the thinking behind our work at the upcoming #EASD2026# conference in Milan, Italy. Read more about our approach:
Show more
Millions of people live with diabetes and obesity, and the science keeps moving forward. This month, researchers and clinicians will gather in Milan for #EASD2026#. We'll be there, sharing new findings as we work together to advance cardiometabolic health:
Show more
